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1. Introduction 
Tyrosine aminotransferase activity has been found 
in cytosol and in mitochondria of a variety of tissues 
[l-4]. The enzyme from rat liver has been the sub- 
ject of the greatest scrutiny, because of its abundance 
in the organ. The majority of the enzyme from this 
tissue is soluble and can be separated into 3 or 4 
multiple forms by chromatography on hydroxyl- 
apatite [5] or carboxymethyl-Sephadex [6]. The 
mitochondrial enzyme is much less aburidant but 
seems to have a broader tissue distribution than the 
cytosol form [7,8] and a wider substrate spectrum [9]. 
The objective of the studies reported here was to 
gain further information about the structural and 
functional relationship of tyrosine aminotransferase 
from different issues. The soluble and the mitochon- 
drial enzymes were analyzed by carboxymethyl 
(CM)-Sephadex chromatography. The enzymes from 
rat kidney and rat brain were studied and compared 
to that of the liver which is glucocorticoid inducible 
[lo]. Tyrosine aminotransferase (TAT) translocated 
into the mitochondria was eluted in one major peak 
at a lower KC1 concentration than the cytosol forms. 
The mitochondrial enzyme is common to liver and 
other tissues and is regulated by a mechanism differ- 
ent from that of soluble tyrosine aminotransferase. 
2. Materials and methods 
2.1. Reagents 
Carboxymethyl-Sephadex C-50 and FicolI-400 
were purchased from Pharmacia nd phenylmethyl- 
ElsevierfNorth-Holland Biomedical Press 
sulfonyl-fluoride (PMSF) from Sigma. The synthetic 
glucocorticoid, dexamethasone, was kindly provided 
by Roussel-UCLAF Co. 
2.2. Animals and tissue preparation 
Male Wistar ats (- 200-250 g body wt) with 
free access to food and water were used. Dexametha- 
sone suspended in 1% gelatin solution was given in 
1 intraperitoneal Injection (10 mg/lOO g body wt) 
8 h before rats were killed by decapitation. All sub- 
sequent procedures were carried out at 0-4°C. 
The liver was immediately perfused via the vena 
cava with 20 ml phosphate buffer A 50 mM (pH 6.5) 
cw-ketoglutarate 2.5 mM, EDTA 1 mM, 2.mercapto- 
ethanol 1 mM, pyridoxal-5’.phosphate 0.1mM and 
PMSF 0.1 mM, removed and homogenized in 2 vol. 
buffer A’ (buffer A containing 0.25 M sucrose) in a 
glass Potter-Elvehjem with 7 up-and-down strokes. 
The homogenate was centrifuged at 800 X g for 
10 min to sediment nuclei and the supernatant then 
centrifuged at 10 000 X g for 10 min. The resulting 
pellet, washed with buffer A’ and centrifuged again 
represents he crude mitochondrial preparation. The 
10 000 X g supernatant was analyzed for soluble TAT 
activity. 
Kidneys and brain were removed and homogenized 
in 4 vol. buffer A’ in the same conditions as described 
for the liver. The homogenate was centrifuged at 
800 X g for 10 min to discard the nuclei. Either the 
mitochondria were sedimented by centrifugation 
(crude mitochondria) or the 800 X g supernatant was 
used directly as a crude extract after a second homog- 
enization as described in section 2.3. 
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2.3. Purification of liver mitochondria 
The mitochondria were purified by the method in 
[ 1 l] described for synaptosomes, slightly modified. 
The crude mitochondrial pellet corresponding to 7 
rat livers was suspended in 15 ml buffer A’ and layered 
on Ficoll gradients (7 layers, 30-2.5%) in 0.25 M 
sucrose-l mM EDTA. The gradients were allowed to 
equilibrate at room temperature for 1 h and cooled at 
4°C for 30 min before a 7 ml sample/tube was applied 
and centrifuged in a SW2.5-2 Beckman rotor at 
25 000 rev./min for 45 min. The pellet and the 
2 lower layers were diluted with 2 vol. buffer A’ and 
centrifuged at 40 000 rev./min for 30 min. The 
mitochondrial pellet was washed with 30 ml buffer A’ 
and centrifuged for 15 min at 16 000 rev./min. 
The crude or purified mitochondria were broken 
by homogenization in a glass Potter-Braun using a 
tightly fitting teflon pestle with 20 up-and-down 
strokes. 
2.4. Carboxymethyl-Sephadex chromatography 
CM-Sephadex (20 g) was hydrated in 2 1 potassium 
phosphate buffer (500 mM, pH 6.5), washed 3 times 
and kept overnight at 4°C. The swollen CM-Sephadex 
was equilibrated with buffer B (potassium phosphate 
50 mM (pH 6.5)cY-ketoglutarate 2.5 mM, EDTA 1 mM, 
2-mercaptoethanol l mM and PMSF 0.1 mM) by washing 
4 times every 24 h with 5 1 buffer. The sample was applied 
on CM-Sephadex columns (1.8 X 23 cm) and washed 
with 50 ml buffer B. Enzyme was eluted with a 400 ml 
linear gradient from O-O.4 M KC1 in buffer B at a 
20 ml/h flow rate. Fractions (5.5 ml) were collected 
and KC1 molarities were measured by conductance. 
Samples (200 ~1) of each fraction were assayed for 
tyrosine aminotransferase activity by the method in 
[ 121. Enzyme is expressed as A ssr units formed/ 
15 min. In all experiments the total recovery of 
enzyme activity in the eluate was > 80%. 
3. Results 
3 .l . Hepatic forms of tyrosine aminotransferase 
The mitochondrial and the soluble forms of the 
enzyme can be separated by CM-Sephadex chro- 
matography as shown in fig.la. The dotted line 
illustrates the resolution of the soluble enzyme into 
three main peaks SIII, SII and SI, eluted at 0.11, 
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Fig.1. Separation of multiple forms of tyrosine aminotrans- 
ferase from rat liver during carboxymethyl-Sephadex 
chromatography. (a) Enzyme patterns from uninduced rat 
liver: (o- - -0) soluble enzyme; (*---0) TAT activity from 
purified mitochondria. (b) Elution profile from dexametha- 
sone induced rat liver: (A-A) TAT activity from purified 
mitochondria. The enzyme analyzed corresponds to 0.5 g 
tissue for the soluble enzyme and to 30 g tissue for the mito- 
chondrial enzyme. 
0.16 and 0.21 M KCl, respectively; this elution 
pattern is very similar to the separation profile 
described [6]. The mitochondrialenzyme was resolved 
into one major peak, Ml, eluted at 0.07 M KC1 and 
two minor peaksM2 and M3. Peak M2 occurs between 
forms SIII and SII at 0.12 M KC1 and exists only in 
mitochondrial preparations whereas peak M3, which 
elutes at around 0.25 M KCl, might represent con- 
tamination of soluble TAT converted into form SI 
during preparation of mitochondria since in vitro con- 
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Table 1 
Tissue distribution of tyrosine aminotransferase ctivity 
Tissue Fraction tested Dexamethasone Repartition of TATa 
induction 
Ml M2 M3 
Liver Crude extractb - 
Crude mitochondria _ 
Purified mitochondria - 
Purified mitochondria + 
Kidney Crude extract - 
Crude mitochondria + or - 
Brain Crude extract _ 
Crude mitochondria + or - 
2.5 - - 
33 16 51 
74 10 16 
40 36 24 
71 29 - 
74 26 - 
87 13 - 
74 23 3 
a Percentage estimated after substraction of the value peak E which corresponds 
exclusively to aspartate aminotransferase 
b For the crude liver extract, the percentage of peak Ml was estimated taking 
into account forms SI, SII and SIII of the soluble enzyme 
version of soluble forms has been frequently reported 
[ 13,141. The levels of forms M2 and M3 are much 
more important in crude mitochondria preparations 
(table 1). A small apparent TAT activity (peak E) was 
measured in the excluded material, which corresponds 
exclusively to aspartate aminotransferase. 
To determine if glucocorticoid treatment affects 
the TAT pattern corresponding to rat liver mitochon- 
dria, the latter were prepared from dexamethasone- 
treated animals where a significant increase of mito- 
chondrial TAT specific activity was observed. The 
distribution of enzyme activity from purified mito- 
chondria of treated animals (fig. 1 b) compared to that 
of untreated rats (fig.la) shows an important relative 
increase in forms M2 and M3 (table 1). 
3.2. Tyrosine aminotransferase from rat kidney 
The determinations of enzyme activity in crude 
extracts (fig.2a) and in mitochondrial fractions 
(fig.2b) show a similar peak distribution which remains 
unaffected under hormonal treatment. The pattern 
can be compared to the one observed for purified 
mitochondria from uninduced rat liver (dotted line). 
Nevertheless, no peak was observed at the level of 
form M3, and the front peak corresponding to aspar- 
tate aminotransferase (peak E) is much higher in kid- 
ney than in liver extracts. Our results confirm earlier 
work which reported that TAT of renal origin was not 
hormone inducible [lo] and was essentially located 
in mitochondria [7,8]. 
3.3. Tyrosine aminotransferase in the rat brain 
As for kidney, the main enzyme activity is located 
in the mitochondria and appears essentially at the 
level of form Ml (fig.3); the amount of TAT activity 
eluted in the M2 region is not negligible (table 1) and 
the front peak corresponding to aspartate amino- 
transferase is very important. Glucocorticoid treat- 
ment did not increase total TAT activity and did not 
significantly affect the pattern of enzymic activity. 
3.4. Further characterization of the mitochondrial 
enzyme 
Form Ml found in the mitochondria is quite 
different from the other forms of tyrosine amino- 
transferase. In contrast with the soluble enzyme 
which is heat resistant, form M 1 is considerably more 
labile: incubation at 65°C for 5 min resulted in loss 
of 30% of the activity. Whereas the soluble forms 
SIII and SII can be easily converted into form SI 
under various environmental conditions or during 
freezing and thawing [ 13 ,141, form Ml remains 
stable and was not converted into any of the soluble 
forms in vitro. 
It has been claimed that mitochondrial enzyme is 
identical to the mitochondrial aspartate aminotrans- 
ferase [7,15,16]. In order to verify this point, we 
studied the elution profile by following separately 
the activities of TAT and of aspartate aminotrans- 
ferase. Aspartate aminotransferase interferes with the 
A as1 assay [ 121. Whereas the excluded peak E 
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Fig.2. Distribution of TAT activity from kidney during CM- 
Sephadex chromatography. (a) Crude extracts corresponding 
to 4-6 kidneys. (b) Crude mitochondrial preparation (4-6 
kidneys). The dotted line in fig.2(b) corresponds to the elu- 
tion profile of the liver mitochondrial enzyme from uninduced 
rat liver which was run on a parallel column. 
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Fig.3. Distribution of tyrosine and aspartate aminotrans- 
ferase activities from kidney. A sample of crude mitochon- 
drial preparation corresponding to 5 kidneys was applied on 
the CM-Sephadex column and the two enzymes were mea- 
sured on separate samples of each fraction. TAT was assayed 
by the method in [ 121 (o-0) whereas aspartate amino- 
transferase was measured by the method in [ 17) using the 
assay set from Boehringer (. - - - .). 
corresponds exclusively to aspartate aminotransferase, 
only 28-3495 of peak Ml represents aspartate amino- 
transferase activity which is associated with the TAT 
activity either for liver, kidney (fig.4) or brain extracts. 
These observations and the slight interference in the 
TAT enzymatic determination when cw-ketoglutarate 
was replaced by oxaloacetate or when 5 mM aspartate 
was added [7] suggest hat form Ml might represent 
a mixture of enzymes. 
The effect of antibodies specific against soluble 
hepatic tyrosine aminotransferase [181 was studied 
on different enzyme preparations. The results in 
table 2 show that antibody does not react with form 
Ml in a significant way. Since the percentage of 
inhibition of enzymatic activity is very close to the 
ratio of forms M2 and M3 present in the extracts, the 
immunologic properties of Ml TAT point to an 
enzyme which differs from the other molecular forms. 
62 
Volume 104, number 1 FEBS LETTERS August 1979 
KCI 
034 M KCI 
i 
I\ 
;iy’- Liver 
!I 
Fracf ions 
4. Discussion 
Study of the molecular forms of tyrosine amino- 
transferase by CM-Sephad~x chromato~aphy shows 
a precise distribution of the enzyme activity whereas, 
in other conditions [9] the enzyme came off over a 
broad range of potassium phosphate concentration. 
TAT translocated into the mitochondria elutes in one 
major form Ml, which is ubiquitous to liver, kidney 
and brain. This form may be related to form I described 
for kidney, heart and brain during TAT activity 
separation on hydroxylapatite column [ 191. 
In the liver, where the glycogen function and the 
catabolism of tyrosine are very important, the soluble 
forms predominate. The precise role of the mitochon- 
drial form of the liver enzyme is not yet known. It 
could provide some special and emergency needs of 
the cell. One unique example has been reported 
where, in absence of the soluble enzyme activity in a 
patient, the mitochondri~ enzyme operates at an 
increased rate [21]. In kidney and brain where the 
enzyme isnot inducible [10,16,20], the mitochondrial 
enzyme is predominant. When the enzyme is bound 
to the mitochondrial membrane, it might present a 
lower affinity for tyrosme [21]. Such a change would 
be especially important in the brain as the catabolic 
role of TAT has to be moderated since the internal 
pool of tyrosine controls the catechol synthesis 1221. 
The presence of form M2 in mitochondria prepa- 
rations probably represents contamination of soluble 
TAT. A small amount of form M2 was present in 
crude mitochond~a prep~ations from brain or 
kidney whereas in liver extracts the amount of form 
M2 increased when the soluble enzyme synthesis was 
induced by glucocorticoids and depended on the 
degree of mitochondria purification (table 1). These 
observations lead to the conclusion that soluble TAT 
has a high affinity for mitochondria nd this property 
is probably the origin of the controversy about the 
inducibility of mitochondrial TAT. Whereas cortisol 
F&.4. Analysis of tyrosine a~o~an~era~ activity from 
brain-during carboxymethyl-Sephadex chromatography. 
(a) Crude extracts (10 brains). (b) Crude mitochondrial 
preparation (12 brains). The dotted line corresponds to the 
elution profile of the enzyme from purified rat liver mito- 
chondria run on a parallel column. 
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Table 2 
Inhibition of tyrosine aminotransferase activity by antibody specific to the 
purified soluble liver enzyme 
Extract tested 1,nhibition 
(percentage) 
Percentage of M2 + M3 
in the extract 
Liver cytosol 95-100 
Liver crude mitochondria 62 62 
Liver purified mitochondria 24 24 
Kidney crude extract 20 13 
Brain crude extract 15 10 
Form Ml 5-10 0 
Antibody against highly purified soluble TAT [ 181 raised in rabbits was used. 
Aliquots of different extracts (from rats which have not been treated by dexa- 
methasone) were incubated at 3% for 1 h with amounts of antibody which lead 
to maximum inhibition. The mixtures were stored for > 2 h at 4’C before being 
assayed for TAT activity according to [ 121. Controls, similarly incubated with 
serum of non-immunized rabbits and assayed in the same conditions, did not 
show any significant inhibition of TAT activity 
has been reported to have little or no effect on the 
induction of mitochondrial enzyme [21,23,24], a 
2-fold increase of the mitochondrial TAT specific 
activity was observed [8] and cortisol shown to 
cause a 70% increase [25]. There are different ways 
of interpreting the existence of form M2. Since it is 
well known that the elution pattern of the soluble 
enzyme depends on the experimental conditions, 
form M2 could simply represent a mixture of the 
classic soluble forms SI and SII. A more attractive 
interpretation would be to imagine that once the 
enzyme adheres to the mitochondrial membrane, it 
may undergo some changes as has been shown for 
other proteins [26]; one might expect that the 
enzyme interacts with some mitochondrial hydro- 
phobic polypeptide which leads to subsequent changes 
in structure and conformation. 
In view of [26,27] which show that changes in 
enzyme localization play a role in metabolic regula- 
tion, it would be interesting to study further form 
Ml and form M2 of the enzyme in order to better 
understand their physiological importance. 
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